Cargando…

Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment

BACKGROUND: Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role....

Descripción completa

Detalles Bibliográficos
Autores principales: Nazarinasab, Masoumeh, Behrouzian, Forouzan, Abdi, Leila, Sadegh Moghaddam, Amir Ali, Sadeghi, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041003/
https://www.ncbi.nlm.nih.gov/pubmed/36994048
http://dx.doi.org/10.4103/jfmpc.jfmpc_1164_22
_version_ 1784912610662023168
author Nazarinasab, Masoumeh
Behrouzian, Forouzan
Abdi, Leila
Sadegh Moghaddam, Amir Ali
Sadeghi, Susan
author_facet Nazarinasab, Masoumeh
Behrouzian, Forouzan
Abdi, Leila
Sadegh Moghaddam, Amir Ali
Sadeghi, Susan
author_sort Nazarinasab, Masoumeh
collection PubMed
description BACKGROUND: Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen. METHODS: In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention. RESULTS: There was no statistically significant difference between the two groups in terms of demographic characteristics (P > 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (P = 0.97, P = 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (P = 0.02 and P = 0.001, respectively). CONCLUSION: Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment.
format Online
Article
Text
id pubmed-10041003
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100410032023-03-28 Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment Nazarinasab, Masoumeh Behrouzian, Forouzan Abdi, Leila Sadegh Moghaddam, Amir Ali Sadeghi, Susan J Family Med Prim Care Original Article BACKGROUND: Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen. METHODS: In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention. RESULTS: There was no statistically significant difference between the two groups in terms of demographic characteristics (P > 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (P = 0.97, P = 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (P = 0.02 and P = 0.001, respectively). CONCLUSION: Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment. Wolters Kluwer - Medknow 2022-12 2023-01-17 /pmc/articles/PMC10041003/ /pubmed/36994048 http://dx.doi.org/10.4103/jfmpc.jfmpc_1164_22 Text en Copyright: © 2023 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Nazarinasab, Masoumeh
Behrouzian, Forouzan
Abdi, Leila
Sadegh Moghaddam, Amir Ali
Sadeghi, Susan
Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
title Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
title_full Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
title_fullStr Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
title_full_unstemmed Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
title_short Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
title_sort investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041003/
https://www.ncbi.nlm.nih.gov/pubmed/36994048
http://dx.doi.org/10.4103/jfmpc.jfmpc_1164_22
work_keys_str_mv AT nazarinasabmasoumeh investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment
AT behrouzianforouzan investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment
AT abdileila investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment
AT sadeghmoghaddamamirali investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment
AT sadeghisusan investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment